IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America
© 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.
Free access to all Sound Bites content
Published on: February 11, 2026
Medical Professional
POLARIX reduced risk subsequent therapies
Dr. Tara Graff describes the reduced need for subsequent therapies when using Pola-R-CHP in LBCL (Video 3/3)
Tara Graff, MD
Dr. Joshua Reuss discusses the design of the BEAMION Lung trial of zongertinib in HER2m NSCLC (Video 1/3)
Joshua Reuss, MD
Dr. Tara Graff reviews the efficacy of Pola-R-CHP in select LBCL subgroups (Video 2/3)
Tara Graff, MD
Dr. Tara Graff discusses the 5-year efficacy of Pola-R-CHP in LBCL (Video 1/3)
Tara Graff, MD
Dr. Eric Singhi describes differentiating safety aspects of cemiplimab in patients with aNSCLC (Video 3/3)
Eric Singhi , MD
Dr. Charu Aggarwal presents intracranial activity for datopotamab deruxtecan in pretreated mNSCLC (Video 3/3)
Charu Aggarwal, MD